These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23364679)

  • 1. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.
    Furey ML; Drevets WC; Hoffman EM; Frankel E; Speer AM; Zarate CA
    JAMA Psychiatry; 2013 Mar; 70(3):280-90. PubMed ID: 23364679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine.
    Furey ML; Drevets WC; Szczepanik J; Khanna A; Nugent A; Zarate CA
    Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25820840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder.
    Szczepanik J; Nugent AC; Drevets WC; Khanna A; Zarate CA; Furey ML
    Psychiatry Res Neuroimaging; 2016 Aug; 254():67-73. PubMed ID: 27366831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.
    Reed JL; Nugent AC; Furey ML; Szczepanik JE; Evans JW; Zarate CA
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2019 Jul; 4(7):610-618. PubMed ID: 30826253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in visual cortical activation and connectivity with prefrontal cortex during working memory updating in major depressive disorder.
    Le TM; Borghi JA; Kujawa AJ; Klein DN; Leung HC
    Neuroimage Clin; 2017; 14():43-53. PubMed ID: 28138426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
    Furey ML; Khanna A; Hoffman EM; Drevets WC
    Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PsychotherapyPlus: augmentation of cognitive behavioral therapy (CBT) with prefrontal transcranial direct current stimulation (tDCS) in major depressive disorder-study design and methodology of a multicenter double-blind randomized placebo-controlled trial.
    Bajbouj M; Aust S; Spies J; Herrera-Melendez AL; Mayer SV; Peters M; Plewnia C; Fallgatter AJ; Frase L; Normann C; Behler N; Wulf L; Brakemeier EL; Padberg F
    Eur Arch Psychiatry Clin Neurosci; 2018 Dec; 268(8):797-808. PubMed ID: 29214483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study.
    Robertson B; Wang L; Diaz MT; Aiello M; Gersing K; Beyer J; Mukundan S; McCarthy G; Doraiswamy PM
    J Clin Psychiatry; 2007 Feb; 68(2):261-7. PubMed ID: 17335325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal prefrontal activity subserving attentional control of emotion in remitted depressed patients during a working memory task with emotional distracters.
    Kerestes R; Ladouceur CD; Meda S; Nathan PJ; Blumberg HP; Maloney K; Ruf B; Saricicek A; Pearlson GD; Bhagwagar Z; Phillips ML
    Psychol Med; 2012 Jan; 42(1):29-40. PubMed ID: 21733287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.
    Ellis JS; Zarate CA; Luckenbaugh DA; Furey ML
    J Affect Disord; 2014 Jun; 162():39-42. PubMed ID: 24767003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study.
    Alders GL; Davis AD; MacQueen G; Strother SC; Hassel S; Zamyadi M; Sharma GB; Arnott SR; Downar J; Harris JK; Lam RW; Milev R; Müller DJ; Ravindran A; Kennedy SH; Frey BN; Minuzzi L; Hall GB;
    J Affect Disord; 2020 Mar; 264():414-424. PubMed ID: 31757619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
    Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
    Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine.
    Fu CH; Costafreda SG; Sankar A; Adams TM; Rasenick MM; Liu P; Donati R; Maglanoc LA; Horton P; Marangell LB
    BMC Psychiatry; 2015 Apr; 15():82. PubMed ID: 25880400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline mood-state measures as predictors of antidepressant response to scopolamine.
    Furey ML; Nugent AC; Speer AM; Luckenbaugh DA; Hoffman EM; Frankel E; Drevets WC; Zarate CA
    Psychiatry Res; 2012 Mar; 196(1):62-7. PubMed ID: 22349648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.
    Drevets WC; Furey ML
    Biol Psychiatry; 2010 Mar; 67(5):432-8. PubMed ID: 20074703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation.
    Rizvi SJ; Salomons TV; Konarski JZ; Downar J; Giacobbe P; McIntyre RS; Kennedy SH
    J Affect Disord; 2013 Nov; 151(2):573-581. PubMed ID: 23948629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.